Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 2, 2011, Pages 234-238

  Strasser, Andrew A ^a   Benowitz, Neal L ^b   Pinto, Angela G ^a   Tang, Kathy Z ^a   Hecht, Stephen S ^c   Carmella, Steve G ^c   Tyndale, Rachel F ^d   Lerman, Caryn E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; NICOTINE;

ADULT; AGED; ARTICLE; CIGARETTE SMOKING; CLEARANCE; FEMALE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTION; PRIORITY JOURNAL; TOPOGRAPHY;

EID: 79951626053     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0674     Document Type: Article

References (36)

1. Ray R, Tyndale RF, Lerman C. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet 2009;23:252-61.
2. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 1997;282:1608-14. (Pubitemid 27408347)
3. Nakajima M, Kwon JT, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H., et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 2001;69:72-8. (Pubitemid 32108674)
4. Strasser AA, Tang KZ, Sanborn PM, Zhou JY, Kozlowski LT. Behavioral filter vent blocking on the first cigarette of the day predicts which smokers of light cigarettes will increase smoke exposure from blocked vents. Exp Clin Psychopharmacol 2009;17:405-12
5. Benowitz NL, Jacob P III, Herrera B. Nicotine intake and dose response when smoking reduced-nicotine content cigarettes. Clin Pharmacol Ther 2006;80:703-14. (Pubitemid 44920221)
6. Djordjevic MV, Stellman SD, Zang E. Doses of nicotine and lung carcinogens delivered to cigarette smokers. J Natl Cancer Inst 2000;92:106-11. (Pubitemid 30089866)
7. Strasser AA, Pickworth WB, Patterson F, Lerman C. Smoking topography predicts abstinence following treatment with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev 2004;13:1800-4. (Pubitemid 39482959)
8. Strasser AA, O'Connor RJ, Mooney ME, Wileyto EP. Digital image analysis of cigarette filter stains as an indicator of compensatory smoking. Cancer Epidemiol Biomarkers Prev 2006;15:2565-9. (Pubitemid 46055198)
9. Dempsey D, Tutka P, Jacob P III, Allen F, Schoedel K, Tyndale RF. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 2004;76:64-72. (Pubitemid 38844735)
10. Benowitz NL, Hukkanen J, Jacob P III. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol 2009;192:29-60.
11. Lea RA, Dickson S, Benowitz NL. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. J Anal Toxicol 2006;30:386-9. (Pubitemid 44274073)
12. Benowitz NL, Pomerleau OF, Pomerleau CS, Jacob P III. Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob Res 2003;5:621-4. (Pubitemid 37304836)
13. Tyndale RF, Sellers EM. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos 2001;29:548-52. (Pubitemid 32275533)
14. London S, Idle J, Daly A, Coetzee G. Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet 1999;353:898-9. (Pubitemid 29126883)
15. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav 2009;92:6-11.
16. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991;86:1119-27.
17. Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, et al. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin Pharmacol Ther 2010. doi: 10.1038/clpt.2010.3.
18. Carmella SG, Han S, Fristad A, Yang Y, Hecht SS. Analysis of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. Cancer Epidemiol Biomarkers Prev 2003;12:1257-61. (Pubitemid 37499454)
19. Strasser AA, Ashare RL, Kozlowski LT, Pickworth WB. The effect of filter vent blocking and smoking topography on carbon monoxide levels in smokers. Pharmacol Biochem Behav 2005;82:320-9. (Pubitemid 41727943)
20. Lee E, Malson JL, Waters AJ, Moolchan ET, Pickworth WB. Smoking topography: reliability and validity in dependent smokers. Nicotine Tob Res 2003;5:673-9. (Pubitemid 37304842)
21. Strasser AA, Lerman C, Sanborn PM, Pickworth W, Feldman E. New lower nicotine cigarettes produce compensatory smoking and increased carbon monoxide exposure. Drug Alcohol Depend 2007;86:294-300. (Pubitemid 44821611)
22. Benowitz NL, Jacob P III, Bernert JT, Wilson M, Wang L, Allen F, et al. Carcinogen exposure during short-term switching from regular to "light" cigarettes. Cancer Epidemiol Biomarkers Prev 2005;14:1376-83.
23. Lerman C, Tyndale RF, Patterson F, Wileyto EP, Shields PG, Pinto A, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation, Clin Pharmacol Ther 2006;79:600-8. (Pubitemid 43817942)
24. Patterson F, Schnoll RA, Wileyto EP, Pinto A, Epstein LH, Shields PG, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 2008;84:320-5.
25. Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P III. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 2006;79:480-8.
26. Strasser AA, Malaiyandi V, Hoffmann E, Tyndale R, Lerman C. An association of CYP2A6 genotype and smoking topography. Nicotine Tob Res 2007;9(4):511-8. (Pubitemid 46534464)
27. Audrain-McGovern J, Al Koudsi N, Rodriguez D, Wileyto EP, Shields PG, Tyndale RF. The role of CYP2A6 in the emergence of nicotine dependence in adolescents. Pediatrics 2007;119:264-74.
28. Benowitz NL, Zevin S, Jacob P III. Suppression of nicotine intake during ad libitum cigarette smoking by high dose transdermal nicotine. J Pharmacol Exp Ther 1998;287:958-62. (Pubitemid 29131607)
29. Swan GE, Benowitz NL, Lessov CN, Jacob P III, Tyndale RF, Wilhelmsen K. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics 2005;15:115-25. (Pubitemid 40562988)
30. Benowitz NL, Dains KM, Dempsey D, Herrera B, Yu L, Jacob P III. Urine nicotine metabolite concentrations in relation to plasma cotinine during low-level nicotine exposure. Nicotine Tob Res 2009;11:954-60.
31. International Agency for Research on Canerer (IARC). Tobacco smoke and involuntary smoking. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon, France: IARC; 2004.
32. Hecht SS. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 2002;3:461-9. (Pubitemid 34863666)
33. Hecht SS. Tobacco smoke carcinogens and lung cancer. J NatlCancer Inst 1999;91:1194-210. (Pubitemid 29357186)
34. United States Department of Health and Human Services. The health consequences of smoking: a report of the surgeon general. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
35. Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung cancer risk. JAMA 2005;294:1505-10. (Pubitemid 41362687)
36. Muscat JE, Stellman SD, Caraballo RS, Richie JP Jr. Time to first cigarette after waking predicts cotinine levels. Cancer Epidemiol Biomarkers Prev 2009;18:3415-20.